Future Considerations for Pneumococcal Vaccination

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVPMary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

The key opinion leaders examine the recent approval of PCV21, assessing its potential influence on pneumococcal vaccination strategies, while also identifying and discussing current unmet needs in the field of pneumococcal vaccination.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

EP: 11.Insights on Conjugate Pneumococcal Vaccines

Now Viewing

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

How will the recent approval of PCV21 impact pneumococcal vaccination decision making?
What are the current unmet needs in the field of pneumococcal vaccination?